Equities

Turnstone Biologics Corp

TSBX:NMQ

Turnstone Biologics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5339
  • Today's Change0.007 / 1.33%
  • Shares traded214.46k
  • 1 Year change-75.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Turnstone Biologics Corp's revenues fell -73.66% from 73.30m to 19.31m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 30.83m to a larger loss of 55.20m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-98.52%
Return on equity--
Return on investment-127.31%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Turnstone Biologics Corp fell by 17.20m. Cash Flow from Financing totalled 77.05m or 399.08% of revenues. In addition the company used 66.15m for operations while cash used for investing totalled 28.09m.
Cash flow per share-3.34
Price/Cash flow per share--
Book value per share2.58
Tangible book value per share2.58
More ▼

Balance sheet in USDView more

Turnstone Biologics Corp appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.38
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -241.67%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.